Kidney cancer study reveals Real-World use of top drug combos
NCT ID NCT06345183
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at 327 adults with advanced kidney cancer who received one of two drug combinations (nivolumab+ipilimumab or pembrolizumab+lenvatinib) in real-world U.S. clinics. Researchers collected data on patient characteristics, treatment patterns, and outcomes from medical records. The goal was to describe how these approved therapies are actually used outside of clinical trials, not to test new treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED RENAL CELL CARCINOMA (ARCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cardinal Health
Dublin, Ohio, 43017, United States